Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
HIPPURAN I 131 (Iodohippurate Sodium I-131) is a radioactive diagnostic agent administered by injection used for renal imaging and function assessment. It is an organoiodine compound that localizes in the kidneys, enabling visualization of renal perfusion and excretion through nuclear imaging. This product represents a legacy diagnostic radiopharmaceutical with decades of clinical utility in nephrology and urology.
With LOE approaching and minimal linked job activity, this diagnostic radiopharmaceutical faces declining commercial relevance, likely resulting in smaller brand teams and reduced investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HIPPURAN I 131 offers limited career growth potential given zero linked job openings and LOE status. Positions available are primarily focused on lifecycle management, compliance, and operational maintenance rather than commercial expansion or innovation.
Worked on HIPPURAN I 131 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.